Novo Nordisk shares fell up to 9% after its capital markets day, as investors found its growth plans underwhelming amid competition from Eli Lilly and looming patent expirations ▻ ↧ Wegovy maker Novo shares slump as management grilled on pricing, M&A Novo Nordisk shares slid as much as 9% on Monday as executives faced tough questions from analysts over the drugmaker's pricing power and dealmaking strategy ahead of looming patent expiries.
published
Novo Nordisk shares fell up to 9% after its capital markets day, as investors found its growth plans underwhelming amid competition from Eli Lilly and looming patent expirations ▻
Open the original public source →
Latest documented BWB result
$APP market result
Exit $APP Sold Puts for a nice profit and then sold more Puts - this time the $325's for $3.97
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.